Vanda Pharmaceuticals posts Q3 2026 revenue up 24% and raises full‑year guidance above $240 M
Vanda Pharmaceuticals reported third‑quarter 2026 revenue of $69.8 million, a 24% year‑over‑year increase, and operating expenses of $93.3 million, down 18% sequentially. Net loss before income taxes was $22.4 million and cash balances fell to $140.5 million. Management announced a commercial launch of BYSANTI in Q4 2026 and raised full‑year 2026 revenue guidance to exceed $240 million, citing positive Phase III data for NEREUS.
Why it matters
The earnings beat and higher guidance suggest stronger cash flow prospects, which may support the upcoming BYSANTI launch and future FDA approvals (the company expects full‑year revenue >$240 M, per the earnings release). The reduced operating expenses and cash position provide insight into the company’s near‑term liquidity.
Key facts
- 1Q3 2026 total revenues increased 24% year‑over‑year to $69.8 million. prnewswire.com
- 2Q3 2026 total operating expenses decreased 18% sequentially to $93.3 million. prnewswire.com
- 3Loss before income taxes was $22.4 million in Q3 2026. prnewswire.com
- 4Cash, cash equivalents and marketable securities totaled $140.5 million as of September 30 2026. prnewswire.com
- 5Management expects BYSANTI to launch in Q4 2026. prnewswire.com
- 6Full‑year 2026 revenue guidance was raised to exceed $240 million. finance.yahoo.com
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.